Seroatlas · Human Serome Atlas

NAGA

Alpha-N-acetylgalactosaminidase

Also known as: D22S674, NAGAB_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P17050
Gene
NAGA
Ensembl
ENSG00000198951
Chromosome
22
Canonical length
411 aa
Protein class
Cancer-related genes, Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Secretome location
Intracellular and membrane
Quaternary structure
Homodimer

OverviewNCBI Gene

NAGA encodes the lysosomal enzyme alpha-N-acetylgalactosaminidase, which cleaves alpha-N-acetylgalactosaminyl moieties from glycoconjugates. Mutations in NAGA have been identified as the cause of Schindler disease types I and II (type II also known as Kanzaki disease). [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

411 residues, UniProt reviewed canonical sequence.

>P17050|NAGA
     1  MLLKTVLLLG HVAQVLMLDN GLLQTPPMGW LAWERFRCNI NCDEDPKNCI SEQLFMEMAD
    61  RMAQDGWRDM GYTYLNIDDC WIGGRDASGR LMPDPKRFPH GIPFLADYVH SLGLKLGIYA
   121  DMGNFTCMGY PGTTLDKVVQ DAQTFAEWKV DMLKLDGCFS TPEERAQGYP KMAAALNATG
   181  RPIAFSCSWP AYEGGLPPRV NYSLLADICN LWRNYDDIQD SWWSVLSILN WFVEHQDILQ
   241  PVAGPGHWND PDMLLIGNFG LSLEQSRAQM ALWTVLAAPL LMSTDLRTIS AQNMDILQNP
   301  LMIKINQDPL GIQGRRIHKE KSLIEVYMRP LSNKASALVF FSCRTDMPYR YHSSLGQLNF
   361  TGSVIYEAQD VYSGDIISGL RDETNFTVII NPSGVVMWYL YPIKNLEMSQ Q

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NAGA can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.23
Highest tissue expression
40 nTPM

Expression across tissuesHPA

Tissue

  • placenta: 40 nTPM
  • parathyroid gland: 37 nTPM
  • choroid plexus: 32 nTPM
  • appendix: 31 nTPM
  • liver: 30 nTPM
  • smooth muscle: 26 nTPM

Single-cell type

  • hofbauer cells: 117 nCPM
  • extravillous trophoblasts: 91 nCPM
  • syncytiotrophoblasts: 66 nCPM
  • kupffer cells: 61 nCPM
  • monocytes: 60 nCPM
  • cytotrophoblasts: 54 nCPM

Immune cell

  • non-classical monocyte: 259 nTPM
  • intermediate monocyte: 249 nTPM
  • classical monocyte: 203 nTPM
  • myeloid DC: 195 nTPM
  • total PBMC: 121 nTPM
  • plasmacytoid DC: 120 nTPM

Brain region

  • choroid plexus: 30 nTPM
  • white matter: 25 nTPM
  • medulla oblongata: 24 nTPM
  • spinal cord: 21 nTPM
  • thalamus: 20 nTPM
  • hypothalamus: 19 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NAGA.

Disease | AllUniProt

Conditions NAGA is implicated in, by any mechanism.

Disease | GeneticClinVar

42 pathogenic / likely-pathogenic of 442 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Alpha-N-acetylgalactosaminidase deficiency type 1
  • Alpha-N-acetylgalactosaminidase deficiency type 2
  • Alpha-N-acetylgalactosaminidase deficiency
  • Alpha-N-acetylgalactosaminidase deficiency type 3
  • Malignant tumor of esophagus

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.3
gnomAD pLI
0
gnomAD missense Z
0.17
DepMap mean gene effect
0.01
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NAGA as an antibody target. Whether an autoantibody or antibody against NAGA could matter depends on whether native NAGA is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NAGA is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label NAGA as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/NAGA. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...